Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†

(2014) I. A. McNeish et al.   ANNALS OF ONCOLOGY

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS

(2013) Xiang-Hua Zhang et al.   CANCER BIOLOGY & THERAPY

Role of Focal Adhesion Kinase in Regulating YB–1–Mediated Paclitaxel Resistance in Ovarian Cancer

(2013) Yu Kang et al.   JNCI-Journal of the National Cancer Institute

Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies

(2012) S. Murray et al.   CANCER TREATMENT REVIEWS

Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer

(2012) Xiaochun Zhang et al.   RADIOTHERAPY AND ONCOLOGY

Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer

(2011) N. Syed et al.   CANCER RESEARCH

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

(2011) Gottfried E. Konecny et al.   CLINICAL CANCER RESEARCH

Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells

(2011) Claire M. Connell et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

(2011) Beth Y. Karlan et al.   JOURNAL OF CLINICAL ONCOLOGY

The coxsackie–adenovirus receptor induces an inflammatory cardiomyopathy independent of viral infection

(2011) Stella Yuen et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Guidelines for the welfare and use of animals in cancer research

(2010) P Workman et al.   BRITISH JOURNAL OF CANCER

Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells

(2010) Yue Wang et al.   CANCER LETTERS

A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases

(2010) K. J. Kimball et al.   CLINICAL CANCER RESEARCH

p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker

(2010) Magdalena B Flak et al.   Molecular Cancer

Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer

(2010) C K Ingemarsdotter et al.   ONCOGENE

Role of epigenomics in ovarian and endometrial cancers

(2010) Curtis Balch et al.   Epigenomics

Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

(2009) D. Etemadmoghadam et al.   CLINICAL CANCER RESEARCH

Coxsackie adenovirus receptor (CAR) regulates integrin function through activation of p44/42 MAPK

(2009) Charlotte Farmer et al.   EXPERIMENTAL CELL RESEARCH

Chromosomal instability determines taxane response

(2009) C. Swanton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nuclear Survivin Abrogates Multiple Cell Cycle Checkpoints and Enhances Viral Oncolysis

(2008) C. M. Connell et al.   CANCER RESEARCH

Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer

(2008) Irene Kuhn et al.   PLoS One

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY